{"entity":{"id":"lars-bullinger","kind":"person","name":"Lars Bullinger","aka":[],"tldr":"Lars Bullinger is a haematologist and AML genomics researcher leading Charité's haematology department.","summary":"Lars Bullinger is Director of the Department of Hematology, Oncology and Tumor Immunology at Charité Universitätsmedizin Berlin. A haematologist, his specialisms are acute myeloid leukaemia, leukaemia genomics and haematology. His work on gene expression and genomic classification of acute myeloid leukaemia contributed to the risk stratification systems used in the disease. His Blood papers include a study of clonal evolution in FLT3-ITD acute myeloid leukaemia under midostaurin, an international study of the genomic landscape and clonal evolution of leukaemia with t(8;21), and a report on measurable residual disease monitoring in t(8;21) leukaemia from the AML Study Group. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bullinger%20L%5BAuthor%5D%20AML"}],"tags":[],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["charite"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Hematology, Oncology and Tumor Immunology, Charité","institutionId":"charite","specialisms":["Acute myeloid leukaemia","Leukaemia genomics","Haematology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bullinger%20L%5BAuthor%5D%20AML"}],"papers":[{"title":"Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin","journal":"Blood","year":2021,"doi":"10.1182/blood.2020007626"},{"title":"Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients","journal":"Blood","year":2019,"doi":"10.1182/blood-2018-05-852822"},{"title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group","journal":"Blood","year":2019,"doi":"10.1182/blood.2019001425"}],"orcid":"0000-0002-5890-5510"},"route":"/people/lars-bullinger/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"institution":[{"id":"charite","kind":"institution","name":"Charité Universitätsmedizin Berlin","route":"/institutions/charite/"},{"id":"eha","kind":"institution","name":"European Hematology Association","route":"/institutions/eha/"}]}}